YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center
Patients with intermediate-risk papillary thyroid cancer who undergo lobectomy versus total thyroidectomy as the surgical approach show no significant differences in recurrence-free survival.